O	0	16	Characterization	Characterization	NN	B-NP
O	17	19	of	of	IN	B-PP
O	20	31	transferrin	transferrin	NN	B-NP
O	32	42	glycoforms	glycoform	NNS	I-NP
O	43	45	in	in	IN	B-PP
O	46	51	human	human	JJ	B-NP
B-Organism_substance	52	57	serum	serum	NN	I-NP
O	58	60	by	by	IN	B-PP
O	61	63	CE	CE	NN	B-NP
O	63	64	-	-	HYPH	B-NP
O	64	66	UV	UV	NN	I-NP
O	67	70	and	and	CC	I-NP
O	71	73	CE	CE	NN	I-NP
O	73	74	-	-	HYPH	B-NP
O	74	77	ESI	ESI	NN	I-NP
O	77	78	-	-	HYPH	I-NP
O	78	80	MS	MS	NN	I-NP
O	80	81	.	.	.	O

O	82	87	Human	Human	JJ	B-NP
O	88	99	transferrin	transferrin	NN	I-NP
O	100	101	(	(	(	O
O	101	103	Tf	Tf	NN	B-NP
O	103	104	)	)	)	O
O	105	107	is	be	VBZ	B-VP
O	108	109	a	a	DT	B-NP
O	110	115	model	model	JJ	I-NP
O	116	128	glycoprotein	glycoprotein	NN	I-NP
O	129	132	for	for	IN	B-PP
O	133	143	congenital	congenital	JJ	B-NP
O	144	153	disorders	disorder	NNS	I-NP
O	154	156	of	of	IN	B-PP
O	157	170	glycosylation	glycosylation	NN	B-NP
O	171	172	(	(	(	O
O	172	175	CDG	CDG	NN	B-NP
O	175	176	)	)	)	O
O	177	186	diagnosis	diagnosis	NN	B-NP
O	186	187	.	.	.	O

O	188	190	In	In	IN	B-PP
O	191	194	the	the	DT	B-NP
O	195	199	last	last	JJ	I-NP
O	200	203	few	few	JJ	I-NP
O	204	209	years	year	NNS	I-NP
O	209	210	,	,	,	O
O	211	214	new	new	JJ	B-NP
O	215	217	CE	CE	NN	I-NP
O	217	218	-	-	HYPH	B-NP
O	218	220	UV	UV	NN	I-NP
O	221	228	methods	method	NNS	I-NP
O	229	232	for	for	IN	B-PP
O	233	239	intact	intact	JJ	B-NP
O	240	242	Tf	Tf	NN	I-NP
O	243	253	glycoforms	glycoform	NNS	I-NP
O	254	262	analysis	analysis	NN	I-NP
O	263	267	have	have	VBP	B-VP
O	268	272	been	be	VBN	I-VP
O	273	282	developed	develop	VBN	I-VP
O	283	288	using	use	VBG	B-VP
O	289	300	nonvolatile	nonvolatile	JJ	B-NP
O	301	305	BGEs	BGE	NNS	I-NP
O	306	309	and	and	CC	O
O	310	317	organic	organic	JJ	B-NP
O	318	327	modifiers	modifier	NNS	I-NP
O	327	328	.	.	.	O

O	329	336	However	However	RB	B-ADVP
O	336	337	,	,	,	O
O	338	341	the	the	DT	B-NP
O	342	345	use	use	NN	I-NP
O	346	348	of	of	IN	B-PP
O	349	354	these	these	DT	B-NP
O	355	359	BGEs	BGE	NNS	I-NP
O	360	364	does	do	VBZ	B-VP
O	365	368	not	not	RB	I-VP
O	369	374	allow	allow	VB	I-VP
O	375	378	the	the	DT	B-NP
O	379	387	coupling	coupling	NN	I-NP
O	388	390	of	of	IN	B-PP
O	391	396	these	these	DT	B-NP
O	397	407	procedures	procedure	NNS	I-NP
O	408	412	with	with	IN	B-PP
O	413	425	electrospray	electrospray	NN	B-NP
O	426	428	MS	MS	NN	I-NP
O	429	430	(	(	(	O
O	430	433	ESI	ESI	NN	B-NP
O	433	434	-	-	HYPH	B-NP
O	434	436	MS	MS	NN	I-NP
O	436	437	)	)	)	O
O	437	438	.	.	.	O

O	439	441	In	In	IN	B-PP
O	442	446	this	this	DT	B-NP
O	447	452	study	study	NN	I-NP
O	452	453	,	,	,	O
O	454	455	a	a	DT	B-NP
O	456	459	new	new	JJ	I-NP
O	460	462	CE	CE	NN	I-NP
O	462	463	-	-	HYPH	I-NP
O	463	465	UV	UV	NN	I-NP
O	466	476	separation	separation	NN	I-NP
O	477	483	method	method	NN	I-NP
O	484	486	of	of	IN	B-PP
O	487	489	Tf	Tf	NN	B-NP
O	490	500	glycoforms	glycoform	NNS	I-NP
O	501	503	is	be	VBZ	B-VP
O	504	513	developed	develop	VBN	I-VP
O	513	514	,	,	,	O
O	515	520	using	use	VBG	B-VP
O	521	522	a	a	DT	B-NP
O	523	529	double	double	JJ	I-NP
O	529	530	-	-	HYPH	I-NP
O	530	535	layer	layer	NN	I-NP
O	536	542	stable	stable	JJ	I-NP
O	543	550	coating	coating	NN	I-NP
O	551	554	and	and	CC	O
O	555	556	a	a	DT	B-NP
O	557	565	volatile	volatile	JJ	I-NP
O	566	569	BGE	BGE	NN	I-NP
O	570	575	based	base	VBN	B-VP
O	576	578	on	on	IN	B-PP
O	579	587	ammonium	ammonium	NN	B-NP
O	588	595	acetate	acetate	NN	I-NP
O	595	596	.	.	.	O

O	597	600	The	The	DT	B-NP
O	601	611	separation	separation	NN	I-NP
O	612	618	method	method	NN	I-NP
O	619	621	is	be	VBZ	B-VP
O	622	631	optimized	optimize	VBN	I-VP
O	632	637	using	use	VBG	B-VP
O	638	646	standard	standard	JJ	B-NP
O	647	649	Tf	Tf	NN	I-NP
O	650	653	and	and	CC	O
O	654	659	their	their	PRP$	B-NP
O	660	669	potential	potential	NN	I-NP
O	670	672	is	be	VBZ	B-VP
O	673	685	demonstrated	demonstrate	VBN	I-VP
O	686	694	applying	apply	VBG	I-VP
O	695	698	the	the	DT	B-NP
O	699	705	method	method	NN	I-NP
O	706	708	to	to	TO	B-PP
O	709	712	the	the	DT	B-NP
O	713	721	analysis	analysis	NN	I-NP
O	722	724	of	of	IN	B-PP
B-Organism_substance	725	729	sera	sera	NN	B-NP
O	730	732	Tf	Tf	NN	I-NP
O	733	737	from	from	IN	B-PP
O	738	745	healthy	healthy	JJ	B-NP
O	746	757	individuals	individual	NNS	I-NP
O	758	761	and	and	CC	O
O	762	765	CDG	CDG	NN	B-NP
O	766	774	patients	patient	NNS	I-NP
O	774	775	.	.	.	O

O	776	779	The	The	DT	B-NP
O	780	782	CE	CE	NN	I-NP
O	782	783	-	-	HYPH	I-NP
O	783	785	UV	UV	NN	I-NP
O	786	796	separation	separation	NN	I-NP
O	797	803	method	method	NN	I-NP
O	804	807	has	have	VBZ	B-VP
O	808	812	been	be	VBN	I-VP
O	813	820	coupled	couple	VBN	I-VP
O	821	823	to	to	TO	B-PP
O	824	827	ESI	ESI	NN	B-NP
O	827	828	-	-	HYPH	B-NP
O	828	830	MS	MS	NN	I-NP
O	831	840	detection	detection	NN	I-NP
O	840	841	.	.	.	O

O	842	846	Main	Main	NNP	B-NP
O	847	857	parameters	parameter	NNS	I-NP
O	858	862	such	such	JJ	B-PP
O	863	865	as	as	IN	I-PP
O	866	872	sheath	sheath	NN	B-NP
O	873	879	liquid	liquid	NN	I-NP
O	880	891	composition	composition	NN	I-NP
O	892	895	are	be	VBP	B-VP
O	896	905	optimized	optimize	VBN	I-VP
O	906	908	in	in	IN	B-SBAR
O	909	914	order	order	NN	O
O	915	917	to	to	TO	B-VP
O	918	924	obtain	obtain	VB	I-VP
O	925	926	a	a	DT	B-NP
O	927	931	good	good	JJ	I-NP
O	932	943	sensitivity	sensitivity	NN	I-NP
O	943	944	.	.	.	O

O	945	948	The	The	DT	B-NP
O	949	951	CE	CE	NN	I-NP
O	951	952	-	-	HYPH	B-NP
O	952	955	ESI	ESI	NN	I-NP
O	955	956	-	-	HYPH	I-NP
O	956	958	MS	MS	NN	I-NP
O	959	965	method	method	NN	I-NP
O	966	969	has	have	VBZ	B-VP
O	970	974	also	also	RB	I-VP
O	975	979	been	be	VBN	I-VP
O	980	984	used	use	VBN	I-VP
O	985	987	in	in	IN	B-PP
B-Organism_substance	988	993	serum	serum	NN	B-NP
I-Organism_substance	994	1001	samples	sample	NNS	I-NP
O	1002	1011	obtaining	obtain	VBG	B-VP
O	1012	1015	the	the	DT	B-NP
O	1016	1026	separation	separation	NN	I-NP
O	1027	1029	of	of	IN	B-PP
O	1030	1033	the	the	DT	B-NP
O	1034	1043	different	different	JJ	I-NP
O	1044	1052	proteins	protein	NNS	I-NP
O	1053	1060	present	present	JJ	B-ADJP
O	1061	1063	in	in	IN	B-PP
B-Organism_substance	1064	1069	serum	serum	NN	B-NP
O	1070	1073	and	and	CC	O
O	1074	1081	partial	partial	JJ	B-NP
O	1082	1092	separation	separation	NN	I-NP
O	1093	1095	of	of	IN	B-PP
O	1096	1098	Tf	Tf	NN	B-NP
O	1099	1109	glycoforms	glycoform	NNS	I-NP
O	1109	1110	.	.	.	O

O	1111	1120	Different	Different	JJ	B-NP
O	1121	1125	mass	mass	NN	I-NP
O	1126	1133	spectra	spectrum	NNS	I-NP
O	1134	1137	and	and	CC	O
O	1138	1150	deconvoluted	deconvolute	VBD	B-VP
O	1151	1160	molecular	molecular	JJ	B-NP
O	1161	1167	masses	mass	NNS	I-NP
O	1168	1172	were	be	VBD	B-VP
O	1173	1181	obtained	obtain	VBN	I-VP
O	1182	1185	for	for	IN	B-PP
O	1186	1190	each	each	DT	B-NP
O	1191	1200	sialoform	sialoform	NN	I-NP
O	1200	1201	,	,	,	O
O	1202	1210	allowing	allow	VBG	B-VP
O	1211	1222	unequivocal	unequivocal	JJ	B-NP
O	1223	1232	glycoform	glycoform	NN	I-NP
O	1233	1247	identification	identification	NN	I-NP
O	1247	1248	.	.	.	O

